Director Jack Bendheim, who also serves as President and Chief Executive Officer of Phibro Animal Health Corp (NASDAQ: PAHC), indirectly sold 5,280 shares of Class A Common Stock on March 13, 2026. The aggregate proceeds from that disposal totaled $258,244, with sale prices recorded between $48.48 and $49.32 per share.
Those share sales were carried out under a pre-existing Rule 10b5-1 trading arrangement established by BFI Co., LLC on December 11, 2025. BFI Co., LLC is an entity over which Mr. Bendheim exercises voting and dispositive power. On March 12, 2026, BFI Co., LLC converted 100,000 shares of Class B Common Stock into Class A Common Stock.
After the conversion and the March 13 sales, BFI Co., LLC holds an indirect stake of 96,200 Class A shares. Separately, Mr. Bendheim maintains direct ownership of 16,840 shares of Class A Common Stock.
Market interest in the shares has been notable. The stock price subsequently reached $51.17, and the company’s equity has registered a 137% gain over the prior 12-month period. At the same time, InvestingPro analysis referenced in company reporting places PAHC above its calculated Fair Value, categorizing it among stocks that are currently overvalued according to that assessment.
Phibro Animal Health also disclosed its fiscal second-quarter 2026 results, which exceeded consensus estimates. Reported earnings per share came in at $0.87 versus an expected $0.68, representing a 27.94% earnings surprise. Revenue for the quarter was $373.9 million, topping the $355.24 million projection by 5.25%.
Company commentary and market reaction described a positive response to the quarterly results, though specific intraday price movements are not detailed in the disclosures provided. Investors and analysts are using the combination of insider transactions, share conversion activity and the quarterly outperformance to evaluate Phibro’s financial position and operational execution.
Note on information scope - This article reports the transactions, ownership changes and quarterly figures as disclosed. Where third-party valuation commentary is cited, it reflects the InvestingPro assessment referenced in the company disclosures.